ABUS Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
1.0M
-99.4%
179.1M
+16943.4%
1.1M
+98.7%
529.0K
-95.1%
10.7M
Cost of Revenue
0
0
0
0
0
Gross Profit
1.0M
-99.4%
179.1M
+16943.4%
1.1M
+98.7%
529.0K
-95.1%
10.7M
Operating Expenses
7.0M
-31.7%
10.2M
+61.1%
6.3M
-31.0%
9.2M
-0.7%
9.3M
R&D
2.9M
-29.7%
4.1M
-17.7%
5.0M
-13.4%
5.8M
+5.1%
5.5M
SG&A
3.9M
-34.3%
5.9M
+59.6%
3.7M
+21.2%
3.0M
-8.5%
3.3M
Operating Income
-5964000
-103.5%
168.9M
+3293.0%
-5290000
+38.9%
-8659000
-681.9%
1.5M
EBITDA
-5953000
-103.5%
168.9M
+3494.7%
-4976000
+41.8%
-8550000
-613.8%
1.7M
Net Income
-5192000
-103.1%
169.7M
+4618.0%
-3756000
+51.5%
-7742000
-409.4%
2.5M
EPS (Basic)
$-0.03
-103.4%
$0.88
+4500.0%
$-0.02
+50.0%
$-0.04
-500.0%
$0.01
EPS (Diluted)
$-0.03
-103.4%
$0.87
+4450.0%
$-0.02
+50.0%
$-0.04
-500.0%
$0.01
Shares (Diluted)
197.5M
+1.2%
195.2M
+1.9%
191.5M
-0.1%
191.8M
-0.3%
192.4M
Arbutus Biopharma (ABUS) โ€” Financials